IGF Oncology is a biotech company developing targeted anti-cancer drugs with better efficacy and lower side effects compared to existing chemotherapy treatments. Our lead drug, IGF-MTX, targets the deadly blood cancer MDS, and is currently in clinical trials at the Mayo Clinic, and the results so far are very promising.